A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

NCT01975519 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Soft Tissue Sarcoma

Interventions

DRUG: TRC105 and Pazopanib

Sponsor

Tracon Pharmaceuticals Inc.